Literature DB >> 21777198

Targeting aurora kinases in cancer treatment.

Kevin R Kelly1, Jeffrey Ecsedy, Devalingam Mahalingam, Steffan T Nawrocki, Swaminathan Padmanabhan, Francis J Giles, Jennifer S Carew.   

Abstract

The Aurora family of serine/threonine kinases is essential for chromosome alignment, segregation, centrosomal maturation, mitotic spindle formation, and cytokinesis during mitosis. Their fundamental role in cell cycle regulation and aberrant expression in a broad range of malignancies prompted the development of small molecules that selectively inhibit their activity. Recent studies have revealed new insights into the cellular effects of Aurora kinase inhibition. Moreover, early phase clinical studies have shown that these agents have therapeutic efficacy. In this review, we will outline the functions of Aurora kinases in normal cell division and in malignancy. We will focus on recent preclinical and clinical studies that have explored the mechanism of action and clinical effect of Aurora inhibitors in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21777198     DOI: 10.2174/138945011798829410

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  15 in total

Review 1.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

2.  In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor.

Authors:  Senna Sakai; Hiroto Izumi; Yukiko Yoshiura; Yoshifumi Nakayama; Takahiro Yamaguchi; Yoshikazu Harada; Chiho Koi; Hiroyuki Kurata; Yasuo Morimoto
Journal:  Oncol Lett       Date:  2016-09-20       Impact factor: 2.967

3.  Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

Authors:  Catherine M Alder; Martin Ambler; Amanda J Campbell; Aurelie C Champigny; Angela M Deakin; John D Harling; Carol A Harris; Tim Longstaff; Sean Lynn; Aoife C Maxwell; Chris J Mooney; Callum Scullion; Onkar M P Singh; Ian E D Smith; Donald O Somers; Christopher J Tame; Gareth Wayne; Caroline Wilson; James M Woolven
Journal:  ACS Med Chem Lett       Date:  2013-08-12       Impact factor: 4.345

Review 4.  Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

Authors:  Carolien Boeckx; Marc Baay; An Wouters; Pol Specenier; Jan B Vermorken; Marc Peeters; Filip Lardon
Journal:  Oncologist       Date:  2013-07-02

5.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Authors:  Kevin R Kelly; Steffan T Nawrocki; Claudia M Espitia; Mengkun Zhang; Johnny J Yang; Swaminathan Padmanabhan; Jeffrey Ecsedy; Francis J Giles; Jennifer S Carew
Journal:  Int J Cancer       Date:  2012-06-28       Impact factor: 7.396

6.  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

Authors:  Stefan O Ochiana; Vidya Pandarinath; Zhouxi Wang; Rishika Kapoor; Mary Jo Ondrechen; Larry Ruben; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2012-07-31       Impact factor: 6.514

7.  Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.

Authors:  Likun Li; Guang Yang; Chengzhen Ren; Ryuta Tanimoto; Takahiro Hirayama; Jianxiang Wang; David Hawke; Soo Mi Kim; Ju-Seog Lee; Alexei A Goltsov; Sanghee Park; Michael M Ittmann; Patricia Troncoso; Timothy C Thompson
Journal:  Mol Oncol       Date:  2012-12-31       Impact factor: 6.603

8.  Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.

Authors:  Antonino Maria Spartà; Daniela Bressanin; Francesca Chiarini; Annalisa Lonetti; Alessandra Cappellini; Cecilia Evangelisti; Camilla Evangelisti; Fraia Melchionda; Andrea Pession; Alice Bertaina; Franco Locatelli; James A McCubrey; Alberto M Martelli
Journal:  Cell Cycle       Date:  2014-05-29       Impact factor: 4.534

9.  Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.

Authors:  Yangchun Xie; Shan Zhu; Meizuo Zhong; Manhua Yang; Xiaofan Sun; Jinbao Liu; Guido Kroemer; Michael Lotze; Herbert J Zeh; Rui Kang; Daolin Tang
Journal:  Gastroenterology       Date:  2017-07-29       Impact factor: 22.682

10.  The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer.

Authors:  Xin Jin; Qingqing Mo; Yu Zhang; Yue Gao; Yuan Wu; Jing Li; Xing Hao; Ding Ma; Qinglei Gao; Pingbo Chen
Journal:  Cancer Biol Ther       Date:  2016-05-03       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.